Companies
Moderna
mRNA medicine pioneer — Spikevax COVID vaccine and expanding pipeline in flu, RSV, and cancer; proprietary LNP delivery and GMP mRNA manufacturing in Norwood, MA.
- Country
- United States
- Revenue
- $3.2B
- Employees
- ~5,000 emp
FDA GMP
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $2.6 billion raised via convertible notes offering in 2026 | biopharmadive.com |
| Revenue | $1.9 billion in 2025 | nasdaq.com · stocktitan.net |
| Revenue | $145 million in Q2 2026 | last10k.com · sec.gov |
| Production site | Norwood, Massachusetts (Moderna Technology Center); Marlborough, Massachusetts; facilities in the UK, Canada, and Australia | modernatx.com · nasdaq.com · stocktitan.net |
| Headcount | 4,700 employees as of end of fiscal year 2025 | financhle.com · tickerleague.com |
| Regulatory approval | Spikevax (COVID-19), mNEXSPIKE (COVID-19), mRESVIA (RSV), and mCOMBRIAX (Flu+COVID combo, EU approved) | biospace.com · fda.gov · modernatx.com · stocktitan.net |
Independent sources: biopharmadive.com · biospace.com · fda.gov · financhle.com · last10k.com · nasdaq.com · sec.gov · stocktitan.net · tickerleague.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Drug & vaccine development | therapeutics-platforms | High | → |
| mRNA platforms & LNP delivery | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.